Dermatology

The phase 3 DISCREET study explored the safety and efficacy of apremilast in treating patients with moderate to severe genital psoriasis over 32 weeks.

The FDA has announced a proposal to include bemitrizinol to its list of allowable active ingredients to include in sunscreens.

In this interview, Serrao discusses the significance of the phase 2 INTEGUMENT-INFANT study, assessing once-daily roflumilast (Zoryve) cream 0.05% in infants with atopic dermatitis.

From diagnosis, investigators sought to explore psoriasis characteristics, patient demographics, patterns of treatment, and disease progression.

Explore the evolving role of AI in dermatology, balancing its benefits with concerns over accuracy, bias, and the human touch in patient care.

This analysis suggests a potential causal association between psoriasis and depression, highlighting the need for mental health screening in patients with psoriasis.

This study aimed to compare the efficacy and safety of monoclonal antibodies (mAb) for moderate-to-severe atopic dermatitis.

Investigators evaluated current prescription patterns for systemic HS medications among European HS specialists and opinions on criteria for biologic upgrades.

This systematic review and meta-analysis looked at research on the efficacy and safety of topical roflumilast 0.3% in patients with plaque psoriasis.

This FDA News Month in Review provides a round-up of regulatory decisions from November 2025.

This randomized study explored a lower-cost, ambient-light, nonpolarized dermatoscope and its clinical utility in patient-performed teledermoscopy.

This summary of an SDPA Fall session highlights data on the skin microbiome and its impact on dermatologic diseases such as atopic dermatitis.

This December 4 episode of Skin of Color Savvy highlights takeaways from the SOCS Virtual Media Day.

This review of November 2025 highlights several notable news stories covered in the dermatology space.

In this analysis, investigators explored potential impacts of antibiotic exposure on the persistence of biologic treatments in patients living with psoriasis.

Biofrontera announced its submission of a supplemental New Drug Application to the FDA for Ameluz-PDT in superficial basal cell carcinoma (sBCC).

The oral C5aR inhibitor produced durable responses across multiple doses in an 8-week trial, prompting InflaRx to move forward with phase 2b development.

These new data indicate a potential lack of accuracy in hospital-based data on hidradenitis suppurativa (HS) outcomes among those in nonclinical settings.

This global analysis highlights the incidence of psoriasis around the world by 2025, noting various distinctions in region, age groups, and sex.

Board-certified allergist shares how clinicians can better recognize and prevent atopic dermatitis in patients with skin of color, addressing pigmentation.

This research, presented at the SDPA Fall Conference, highlights a consensus report proposing the first formal set of dermoscopy proficiency expectations for PAs.

Kirkorian speaks in this interview about her sessions at SDPA Fall on genetic disorders in pediatric dermatology patients.

Soong discussed the role of allergist's in atopic dermatitis care at a recent HCPLive clinical forum.

Explore the long-term safety and efficacy of JAK inhibitors in atopic dermatitis, enhancing patient care and clinician confidence.

Healthcare providers discuss the importance of effective communication when switching patients from biologics to JAK inhibitors.